Literature DB >> 11826247

Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases.

Jennifer J Marler1, Joshua B Rubin, Nikolaus S Trede, Susan Connors, Holcombe Grier, Joseph Upton, John B Mulliken, Judah Folkman.   

Abstract

We describe 2 cases of angioblastoma, a rare, destructive pediatric tumor, treated with interferon alfa 2b (IFNalpha2b). The first patient is a 10-month-old male who presented with an ulcerated palatal neoplasm that could not be completely resected. The second is a male neonate with a congenital tumor of the right hand that invaded the hypothenar eminence, destroying the fourth and fifth metacarpals. Biopsy in both patients was interpreted as giant cell angioblastoma. Angioblastoma is rare; there is only 1 reported case that necessitated amputation of an upper extremity, also initially recommended for our patient. Because there is little experience with chemotherapy, permission was granted to employ an antiangiogenic regimen of IFNalpha2b. The angiogenic protein, basic fibroblast growth factor (bFGF), was abnormally elevated in both patients. Both patients received IFNalpha2b. In the first child, it was used after incomplete resection, because biopsy-proven tumor was present at the margin and in the nasopharynx. Biopsies 15 months after initiation of IFN2alphab were negative for tumor. Therapy was stopped after 3 years. Eighteen months later, the patient remains disease-free. In the second child, IFNalpha2b was started after debridement of the ulcerated tumor. Over 11 months, the tumor completely regressed and there was bony regeneration of the metacarpals. The fifth digit was amputated because of damage to the metacarpophalangeal joint by the tumor. IFNalpha2b therapy was discontinued after 1 year of treatment, and the child remains disease-free 2 years and 8 months later. In conclusion, this report demonstrates that: 1) a bFGF-overexpressing low-grade tumor can respond to IFNalpha2b in a manner similar to life-threatening infantile hemangiomas, 2) urinary bFGF levels can help guide IFNalpha dosage in such patients, and 3) although bFGF-mediated tumor angiogenesis is inhibited by IFNalpha, physiologic angiogenesis seems to be unaffected.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11826247     DOI: 10.1542/peds.109.2.e37

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  16 in total

1.  Expression of biologically active human interferon alpha 2b in the milk of transgenic mice.

Authors:  Hui Li; Qingyou Liu; Kuiqing Cui; Jinfeng Liu; Yanping Ren; Deshun Shi
Journal:  Transgenic Res       Date:  2012-06-03       Impact factor: 2.788

Review 2.  Interferons as antiangiogenic agents.

Authors:  Daniel J Lindner
Journal:  Curr Oncol Rep       Date:  2002-11       Impact factor: 5.075

Review 3.  Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

4.  Intralesional administration of interferon A for the management of severe haemangiomas.

Authors:  C Kaselas; G Tsikopoulos; G Papouis; V Kaselas
Journal:  Pediatr Surg Int       Date:  2006-12-15       Impact factor: 1.827

5.  Giant cell angioblastoma of bone: four new cases provide further evidence of its distinct clinical and histopathological characteristics.

Authors:  Lin Yu; I Weng Lao; Jian Wang
Journal:  Virchows Arch       Date:  2015-03-28       Impact factor: 4.064

Review 6.  Angiogenesis inhibitors: current strategies and future prospects.

Authors:  Kristina M Cook; William D Figg
Journal:  CA Cancer J Clin       Date:  2010-06-16       Impact factor: 508.702

7.  Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma.

Authors:  Heisoog Kim; Ciprian Catana; Eva-Maria Ratai; Ovidiu C Andronesi; Dominique L Jennings; Tracy T Batchelor; Rakesh K Jain; A Gregory Sorensen
Journal:  Cancer Res       Date:  2011-04-20       Impact factor: 12.701

8.  Use of thalidomide to diminish growth velocity in a life-threatening congenital intracranial hemangioma.

Authors:  Melissa Frei-Jones; Robert C McKinstry; Arie Perry; Jeffrey R Leonard; Tae Sung Park; Joshua B Rubin
Journal:  J Neurosurg Pediatr       Date:  2008-08       Impact factor: 2.375

9.  CD13/APN transcription is regulated by the proto-oncogene c-Maf via an atypical response element.

Authors:  Kathleen M M Mahoney; Nenad Petrovic; Wolfgang Schacke; Linda H Shapiro
Journal:  Gene       Date:  2007-08-25       Impact factor: 3.688

10.  Stabilization of a progressive hemangioblastoma under treatment with thalidomide.

Authors:  Maria Piribauer; Thomas Czech; Karin Dieckmann; Peter Birner; Johannes A Hainfellner; Daniela Prayer; Barbara Fazeny-Dörner; Georg Weinländer; Christine Marosi
Journal:  J Neurooncol       Date:  2004-02       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.